Cellectis

  🧬 What if a simple DNA shape could redefine how we edit stem cells? 🧬   For years, most gene insertion in hematopoietic stem and progenitor cells (HSPCs) relied on viral vectors. Effective, but suboptimal, as it affects HSPCs engraftment and maintenance gene insertion events in vivo.   That’s why our teams explored non-viral alternatives.   The work we publish today in Nature Communications highlights the potential of circular single-stranded DNA (CssDNA) as a new kind of DNA donor template for gene insertion.   The results are encouraging: ✅ CssDNA reached 3–5× higher knock-in efficiency than linear ssDNA, in many cases above 40% ✅ It enabled insertions at multiple loci in HSPCs ✅ CssDNA-edited cells showed a stronger ability to engraft and maintain gene edits in vivo than viral vectors-edited cells   Beyond the numbers, this research suggests a broader shift. If we can reliably perform non-viral insertion of larger sequences, we open the door to new types of cell and gene therapies, ones that are more versatile, programmable, and durable.   How do you see non-viral gene editing evolving over the next five years?   Link to the scientific article in the first comment.

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update. To read the press release: https://lnkd.in/eQ4RShQu

On November 12, join Cellectis at Baird’s Biotech Discovery Series. Our CEO Andre Choulika Ph.D., and our CMO Dr. Adrian Kilcoyne MD MPH MBA, will share the latest Phase 1 results from the BALLI-01 study of lasme-cel - our allogeneic CD22 CAR-T candidate for patients with relapsed or refractory B-ALL. 💡 Why it matters Patients with r/r B-ALL who have exhausted existing therapies face a poor prognosis. Lasme-cel aims to offer an off-the-shelf, ready-to-use CAR-T that can potentially achieve rapid disease control and create a bridge to transplant. 🚀 What’s next The pivotal Phase 2 BALLI-01 study is now underway, with the first patient expected to be enrolled in Q4 2025. In parallel, encouraging preliminary responses have been observed with eti-cel, our dual CD20 and CD22 allogeneic CAR-T candidate in r/r NHL. Additional updates are expected at ASH 2025. At Cellectis, we’re building the next chapter of allogeneic CAR-T therapy: safer, faster, and more accessible. 👉 Don’t wait to register: https://lnkd.in/eZJBAer4

Cellectis is pleased to share new development updates for its allogeneic CAR-T program eti-cel (UCART20x22) to be presented at the American Society of Hematology (ASH) Annual Meeting 2025. Poster 1 – eti-cel (UCART20x22) ✅ Preliminary data show an 86% overall response rate (ORR) and a 57% complete response (CR) among seven patients with relapsed/refractory non-Hodgkin lymphoma (r/r NHL), underscoring eti-cel’s potential to improve outcomes in this difficult-to-treat population. ✅ Preclinical findings demonstrate that combining eti-cel with low-dose IL-2 may enhance and extend anti-tumor activity. ✅ The full Phase 1 dataset, including IL-2 combination cohorts, is expected to be presented in 2026. A second abstract for lasme-cel (UCART22) has been accepted for poster presentation: Poster 2 – lasme-cel (UCART22) ✅ New data highlight a correlation between alemtuzumab exposure and depth of response, supporting the optimization of efficacy without an increase in toxicity in patients with r/r ALL treated with lasme-cel. 👉 To learn more about our abstracts presentations at ASH 2025: https://lnkd.in/e3FD4VRU #ASH2025

Cellectis to Report Third Quarter Financial Results on November 7, 2025 To read the press release: https://lnkd.in/eWBZrhqG

"Cellectis : les signaux sont au vert !" ✅ "De très bonnes datas de phase 1 pour lasmé-cel dans la LAL-B, qui soutiennent l’entrée directe en phase 2 pivotale "   Merci à BIOTECHFINANCES pour ce focus sur notre R&D Day. Notre priorité : traiter les patients atteints de LAL-B en rechute ou réfractaire, dont les besoins sont insatisfaits.   👉 À lire : https://lnkd.in/epd7T8cC

Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL. To read the press release: https://lnkd.in/gNjfq_pw

Cellectis' investors R&D Day >>> it begins Today in NYC, we’re unveiling new data and our next steps for lasme-cel (UCART22) in r/r B-ALL - with oncology experts shaping the future of allogeneic CAR-T. To read our press release: 📄 https://lnkd.in/eq8SwVhq

The unmet need in relapsed/refractory B-ALL is real, and urgent. We’re bringing data, and a plan, to potentially change that. Join us at our R&D Day on Oct 16 (NYC) To register ➡️ cellectis@astrpartners.com

The next chapter in allogeneic CAR-T starts with data. On October 16 in New York City, we’ll share the Phase 1 readout for lasme-cel (UCART22) in r/r B-ALL and our late-stage strategy with some of the brightest minds in oncology that are shaping the future of allogeneic CAR-T.   ➡️ Stay tuned, this will be a high-signal moment.   Investor-only seating. Request an invite at: cellectis@astrpartners.com